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Abstract No consensus has been reached on how to
determine if an immune response has been detected based
on raw data from an ELISPOT assay. The goal of this paper
is to enable investigators to understand and readily imple-
ment currently available methods for response determina-
tion. We describe empirical and statistical approaches,
identifying the strengths and limitations of each approach to
allow readers to rationally select and apply a scientiﬁcally
sound method appropriate to their speciﬁc laboratory set-
ting. Five representative approaches were applied to data
sets from the CIMT Immunoguiding Program and the
response detection and false positive rates were compared.
Simulation studies were also performed to compare
empirical and statistical approaches. Based on these, we
recommend the use of a non-parametric statistical test.
Further, we recommend that six medium control wells or
four wells each for both medium control and experimental
conditions be performed to increase the sensitivity in
detecting a response, that replicates with large variation in
spot counts be ﬁltered out, and that positive responses
arising from experimental spot counts below the estimated
limit of detection be interpreted with caution. Moreover, a
web-based user interface was developed to allow easy
access to the recommended statistical methods. This inter-
face allows the user to upload data from an ELISPOT assay
and obtain an output ﬁle of the binary responses.
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Background
The main goal of monitoring antigen-speciﬁc T cell
responses in immunotherapy trials is to determine if a
treated patient has mounted a response following immune
intervention and if a detected response is associated with a
clinical event. Here, we address the deﬁnition of immune
responses, a prerequisite for determining their clinical
relevance. The IFN-c ELISPOT assay is widely used to
quantify antigen-speciﬁc immunity on a single-cell level.
The assay results in raw data that need to be interpreted by
the investigator to determine if an immune response has
been detected. To date, no commonly accepted consensus
exists as to what rule to use for this determination. This
complicates comparability of results across institutions and
explains the urgent need to establish objective rules with
which to make a response determination. Validation of
ELISPOT standard operating procedures is a critical aspect
but is outside the scope of this paper. A number of statis-
tical methods have been proposed for immune response
determination [e.g., 20, 21] but are not often used by
investigators. The goal of this paper is to enable broader
access by describing currently available statistical methods
to a non-statistical audience (this section), providing real
and simulated data examples to illustrate their use and to
provide the reader with recommendations with respect to
the interpretation of ELISPOT results (‘‘Results’’), and
pointing the reader to a newly created web-based interface
where the recommended statistical methods can be readily
applied to investigators’ data (‘‘Discussion’’).
This paper addresses one part of a larger, recently ini-
tiated effort to harmonize T cell monitoring assays across
institutions [1–6] and to introduce thorough quality control
and extensive validation [7–9]. Our ultimate goal is to
establish T cell immunomonitoring as a precise tool to
guide clinical development and thereby accelerate the
evaluation of new vaccines and immunological therapeu-
tics [10].
Approaches for response deﬁnition
There are two main approaches that are employed to
establish criteria for detecting a positive response for the
ELISPOT assay. The ﬁrst is empirical and the second is
statistical.
Empirical rules
An empirical rule (‘‘ER’’) is usually based on observations
from a speciﬁc study and provides an ad hoc tool to
determine if a positive signal is detected. However, there is
no theoretical basis for this rule. Several empirical
approaches have been proposed in the literature for deter-
mining an ELISPOT response [11–14]. An illustration of a
clear and rational method for deriving an ER to decide
whether an individual is an immunological responder or
not is given by Dubey et al. [14]. Using samples from 72
HIV-negative donors, a comparison was made between
spot counts detected in media with HIV peptide, compared
to peptide-free mock control wells, but matching DMSO
content. The authors then considered the inherent back-
ground of each sample (mock control) and the magnitude
of the antigen-stimulated response.
They used three components to determine their posi-
tivity rule:
1. A minimum threshold ‘‘x’’ for spot counts per 10
6
PBMCs above which would be considered a positive
response if condition 2 below is satisﬁed.
2. A minimum threshold limit ‘‘y’’ for the ratio of antigen
to mock above which would be considered as a
positive response.
3. Based on the generated data with control donors, the
above two thresholds (x and y) were chosen so that
the false positive rate was limited to\1% by analyzing
the responses against HIV-derived control peptides in
HIV-negative donors.
For each of the three control peptide pools tested, they
determined the thresholds that would satisfy these three
criteria. They then applied the rules derived to the data
generated by testing HIV-positive donors and compared the
positivity rates of the different peptide pools. The resulting
deﬁnition for a positive response was more than 55 spots
per 1 9 10
6 cells and at least fourfold background. Dubey
et al. clearly state that the rules they developed are only
valid for the ELISPOT procedures and reagents that were
used to validate them, namely the protocol they used. This
is because it is unknown what the false positive rate would
be in any different setting. Different rules would, therefore,
be necessary for each laboratory using other ELISPOT
protocols or patient populations. The goal of their paper
was to advocate a method for developing an ER but
explicitly not to recommend the speciﬁc cutoff values
(x and y) observed in their experiments, as any laboratory
would have to identify these themselves, based on their
own testing results.
The three data sets from the CIP proﬁciency panel
program that are used in ‘‘Results’’ to illustrate the various
methods contain data from a heterogeneous group of
ELISPOT protocols and hence the approach proposed by
Dubey et al. to determine an ER is not appropriate.
Therefore, we decided to examine two ERs that are used by
many of the participating laboratories. The ﬁrst ER
declares a positive response based on a threshold minimum
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and at least a twofold increase of spot number over back-
ground. The second ER declares a positive response based
only on more than a twofold difference between the spot
counts in the experimental versus background wells. No
minimum spot number is required in the latter rule.
Statistical tests
A statistical test (‘‘ST’’) for response determination is
based on statistical hypothesis testing. This is done by
constructing a null and an alternative hypotheses and then
using the data to test the evidence against the null
hypothesis as outlined in the following three steps:
1. Decide on the appropriate null and alternative hypoth-
eses. A common null hypothesis in the ELISPOT
response determination setting is that there is no
difference between the average (mean) spot counts in
the experimental and control wells. One commonly
used alternative hypothesis is that the mean spot count
in the experimental wells is greater than that of the
background or control wells (a one-sided alternative
hypothesis).
2. Decide on an appropriate test statistic. This depends on
the hypotheses and the characteristics of the data.
3. Set the alpha level or type I error of the test. This alpha
level is used to judge when there is strong evidence
against the null hypothesis. In our setting, responses
will be declared positive if the p value is less than or
equal to alpha. The alpha level is typically set at 0.05
and represents the probability of rejecting the null
hypothesis given the data when in fact the null
hypothesis is true.
The p value is calculated from the assumed distribution
of the test statistic under the null hypothesis so assumptions
about this are needed. If the sample sizes are large (n C 30
is a typical rule of thumb) or the data are known to follow
a normal distribution and the null hypothesis is that
the means of each group are the same, the T statistic
(T = difference in means/pooled standard deviation) can
be chosen as it can be assumed that the T statistic follows a
Student’s t distribution under the null hypothesis. However,
if the sample size is small (e.g., triplicates), or when it is
difﬁcult to estimate the distribution of the population from
which the samples are taken, one cannot assume that the
means follow a normal distribution by the central limit
theorem. In this situation, the T statistic might still be used
but with a non-parametric test (e.g., permutation or boot-
strap) to calculate the p value as this avoids distributional
assumptions.
In the ELISPOT setting, it is often of interest to test
more than one antigen (be it peptide, peptide pool, protein,
or gene) per donor. Therefore, several comparisons will be
made for an individual donor (spot counts from each
antigen versus control). When a ST is used to determine
response, many STs will be performed per donor. This
leads to the problem of multiple comparisons, namely an
inﬂation of the false positive rate. When one ST is per-
formed and a false positive threshold of 0.05 is selected,
the probability of rejecting the null hypothesis when it is
true would be 5%. However, if we perform two indepen-
dent STs with the 0.05 false positive threshold, the prob-
ability that at least one test will be a false positive is 10%.
This probability of at least one false positive among the
multiple hypotheses tested, known as the family-wise error
rate, increases with the number of simultaneous tests per-
formed and can be calculated as 1 - (1 - a)
k, where a is
the false positive threshold for each test and k is the number
of independent comparisons. For three, four or ﬁve con-
current tests, the probability of at least one false positive is
14, 19, or 23%, respectively.
It is of interest to control the family-wise error rate to
ensure that the probability of at least one false positive for
all the STs is at an acceptable level. A classical way to
control the family-wise error rate is to employ a Bonferroni
correction [15]. If there are k planned comparisons and the
desired family-wise error rate is 0.05, the Bonferroni cor-
rection would be to set the type I error threshold for an
individual test to be 0.05/k. The Bonferroni correction is
most appropriate to use when the individual tests are
independent. However, in the ELISPOT setting, the com-
parisons are not independent as all experimental conditions
are compared to the same control wells and responses to
antigens may not be independent due to cross-reactivity
across antigens. Therefore, the Bonferroni correction will
be quite conservative. Many approaches to handle the
problem of multiple comparisons have been developed
both in the independent and dependent settings [15–17]. It
is advisable to use one of these approaches when many
antigens will be tested for response so as to appropriately
control the family-wise error rate.
Several STs have been proposed in the literature for
ELISPOT response determination. A commonly used
method for ELISPOT response determination is the t test
[18] due to the ease of computation of a p value (in Excel
and other programs) and common basic knowledge of the
method and how to apply it. However, the t test assumes
that the sample size is large enough to assume that the test
statistic follows a Student’s t distribution or that the data
are normally distributed. ELISPOT data are not expected to
satisfy these assumptions. Typically, triplicate wells
(n = 3; sometimes even less) are analyzed for each
experimental condition and the responses are count data
that are not generally normally distributed. This has led
others to propose using the Wilcoxon rank sum test [19]o r
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to be normally distributed.
Hudgens et al. [20] evaluated the t test, Wilcoxon rank
sum test, exact binomial test and the Severini test (an
extension of the binomial test) as they would be applied in
the typical ELISPOT setting. They also propose two STs
based on a bootstrap and permutation resampling approach
where the data are pooled across all antigens. These tests
do not assume that the data are normally distributed and
hence are attractive for application to ELISPOT data.
Hudgens et al. also examined several approaches for han-
dling the problem of multiple comparisons. They perform a
series of simulation studies under a variety of scenarios and
examine the family-wise error rate (overall false positive
rate) and the overall sensitivity (positive to at least one
antigen) for each test under each condition. They showed
that the permutation resampling approach with the West-
fall–Young adjustment for multiple comparisons generates
the desired false positive rate while remaining competitive
with the other methods in terms of overall sensitivity. The
authors also applied all of the statistical methods to a real
data set and conﬁrmed some of their simulation results.
Moodie et al. [21] noted that in permuting the data
points across all antigens as proposed by Hudgens et al.,
the results for one antigen could affect the response
detection for another antigen. This is particularly the case
in the setting where one antigen has a strong signal and the
other a weak one, the weak signal may not be detected by
the permutation resampling method. Moodie et al., there-
fore, proposed a different method that does not pool data
across all antigens when permuting, rather the permutations
are done separately for each antigen with the negative
control (background) wells. The authors called this method
distribution free resampling (DFR). For each antigen con-
sidered, the test statistic, the difference in means, is com-
puted for all possible permutations of the antigen and
negative control well data (e.g., 84 possible test statistics
with 3 experimental wells and 6 negative control wells). If
the null hypothesis is true, then the spot counts in the
experimental wells should resemble those in the negative
control wells and permuting or shufﬂing the data across the
experimental and negative control wells should have little
effect on the test statistic. Repeated permutation/shufﬂing
and calculation of the test statistic based on the permuted
data then provides an estimate of the distribution of the test
statistic under the null hypothesis that does not rely on
parametric assumptions (e.g., normality). The test statistic
based on the observed data is then compared to those based
on the permuted data to determine how extreme the
observed test statistic is compared to what might be seen if
the null hypothesis was true. Westfall–Young’s step-down
max T approach is used to calculate p values adjusted for
the multiple comparisons. Moodie et al. then compared an
ER, the permutation resampling approach and their pro-
posed DFR(eq) method, using real and simulated data.
They demonstrated that in some settings their method
outperformed the permutation resampling method in terms
of sensitivity in detecting responses at the antigen level.
A disadvantage of the DFR method is that it should only
be applied in a setting where at least three replicates were
performed for both the control and experimental condi-
tions. In contrast, the permutation resampling method can
be used to make a response determination when there are
only duplicates for either the control or experimental
conditions provided multiple antigens are tested.
The authors have also adapted the DFR(eq) approach
described in [23] for situations in which one wants to test a
stricter null hypothesis and/or control the false positive rate
at a lower level, e.g., 0.01. With the DFR(eq) method, the
minimumpvaluewhencomparingtriplicateantigenwellsto
triplicate control wells will always be above 0.01. Further,
when background levels are high, a larger background-
correcteddifferencemaybeneededforconvincingevidence
ofapositiveresponse.Forexample,abackground-corrected
meanof20per10
6PBMCsmaybelesscompellingwhenthe
mean background is 100 per 10
6 PBMCs and the experi-
mental mean is 120 per 10
6 PBMCs than when the mean
background is 2 and the experimental mean is 22 per 10
6
PBMCs.Thebasicapproachofthemethodissimilartowhat
was previously proposed but with modiﬁcation to the null
and alternative hypotheses. The null hypothesis is that the
mean of the experimental well is less than or equal to twice
the mean of the negative control wells; the alternative is that
it exceeds this. The method uses a slightly different non-
parametric test (bootstrap test instead of the permutation
test) due to the statistical hypotheses under consideration.
The data are log-transformed with negative controls ﬁrst
multipliedbythefactorspeciﬁed inthenullhypothesis(e.g.,
twofold) to reﬂect the data under the null. The experimental
and negative control well data are then sampled with
replacement a large number of times (C1,000) and the test
statistic (difference in means) computed for each. The step-
down max T adjustment is used to calculate adjusted p
values to account for the multiple hypotheses tested. The
selection ofatwofolddifference wasbasedoninvestigators’
biologicalinterestalthoughotherhypothesescanbetestedin
thesamemanner.TheDFR(2x)methodrequiresdatafromat
least three experimental wells with at least three negative
control wells or at least two experimental wells with at least
four negative control wells.
In the next section, we compare the following three STs
for ELISPOT response determination on real data:
1. t test: A one-sided t test (without assuming equal
variance in both groups) comparing the spot counts in
the control wells versus the experimental wells.
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ground and experimental means proposed by Moodie
et al. (DFR(eq)).
3. DFR method with a null hypothesis of less than or
equal to twofold difference between background and
experimental means proposed by Moodie (DFR(2x)).
For all three statistical rules, data that result in p values
less than or equal to 0.05 were considered a positive
response.
Results
In order to evaluate the performance of the methods
described in the previous section, two ERs ([5 spots/
100,000 PBMCs & [2-fold background, [2-fold back-
ground) and the three STs (one-sided t test, DFR(eq), and
DFR(2x)) were applied to results from large data sets that
were generated in three consecutive interlaboratory testing
projects organized by the CIP [22, 23]; data are available
upon request. In the referred studies, groups of 11, 13 and
16 laboratories (phases I, II and III, respectively) quantiﬁed
the number of CD8 T cells speciﬁc for two model antigens
within PBMC samples that were centrally prepared and
then distributed to the participating laboratories. All par-
ticipants were allowed to use their preferred ELISPOT
protocol. Therefore, the data sets generated in these studies
can be considered representative of results generated by a
wide range of different protocols commonly applied within
Europe. Each participating center was asked to test in
triplicate 18 preselected donors (5 in the ﬁrst phase, 8 in the
second phase and 5 in the third phase) with two synthetic
peptides (HLA-A*0201 restricted epitopes of CMV and
Inﬂuenza) as well as PBMCs in medium alone for back-
ground determination. The donors were selected so that 21
donor/antigen combinations (6 in the ﬁrst phase, 8 in the
second phase and 7 in the third phase) were expected to
demonstrate a positive response with the remaining 15
donor/antigen combinations not expected to demonstrate a
positive response. Pretesting of potential donor samples for
the proﬁciency panels was routinely done at two time
points in two independent labs. Only samples from donors
that had consistent results in all four performed experi-
ments were ﬁnally selected for distribution to the partici-
pating centers.
Statistical test versus empirical criteria
Table 1 outlines the response detection rate for each center
based on the empirical and statistical response criteria. The
overall response detection rate from all 19 centers across
all three phases of testing was 59% based on the ﬁrst ER
([5 spots/100,000 PBMCs & [2-fold background), 74%
based on the second ER ([2-fold background), 76% based
on the t test, 75% based on the DFR(eq) method (equal
means), and 61% based on the DFR(2x) method ([2-fold
difference). Table 2 details the false positive response rate
for each center based on the empirical and statistical
response criteria. The overall false positive rate from all 19
centers across all three phases of testing was 3% based on
the ﬁrst ER ([5 spots/100,000 PBMCs & [2-fold back-
ground), 17% based on the second ER ([2-fold back-
ground), 10% based on the t test, 11% based on the
DFR(eq) method (equal means), and 2% based on the
DFR(2x) method ([2-fold difference).
The ﬁrst ER yielded response detection rates that were
lower than those derived from the t test, the DFR(eq)
method and the second ER ([2-fold background). How-
ever, the false positive rates with the ﬁrst ER were similar
to the false positive rate found for DFR(2x), lower than the
false positive rates with the t test or DFR(eq) method and
much lower than the false positive rate of the second ER.
The DFR(eq) method had similar response detection rates
as the t test—only in 17 of 478 comparisons did the con-
clusion of the STs differ. The DFR(eq) method with a null
hypothesis of equal means had higher detection rates
compared to the DFR(2x) method where the null hypoth-
esis was less than or equal to a twofold difference of the
experimental counts over the background. However, the
DFR(eq) also resulted in a higher false-positive rate than
the DFR(2x) method.
There were 478 comparisons made: 282 donor/antigen
combinations versus control expected to demonstrate a
positive response and 196 donor/antigen combinations
versus control expected not to demonstrate a positive
response. There were 20 instances where a response des-
ignation was not possible with both the DFR methods
due to some laboratories having only performed duplicates
for a control or experimental condition. Comparing the
DFR(eq) response determination rule to the ﬁrst ER, there
was disagreement for 76 of the 478 comparisons; for 74
comparisons, the DFR(eq) test declared the triplicate a
positive response while the ER did not while for two
comparisons the reverse was true. Comparing the DFR(eq)
response determination to the second ER ([2-fold back-
ground), there were 50 disagreements: 25 times the
DFR(eq) test declared the triplicate a positive response
while the ER did not and 25 times the ER declared the
triplicate a positive response while the DFR(eq) test did
not. Comparing the DFR(2x) response determination rule
to the ﬁrst ER ([5 spots/100,000 PBMCs & [2-fold
background), there was disagreement for 43 of the 478
comparisons; for 29 comparisons, the DFR(2x) test
declared the triplicate a positive response while the ER did
not while for 14 comparisons the reverse was true.
Cancer Immunol Immunother (2010) 59:1489–1501 1493
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second ER ([2-fold background), there were 58 disagree-
ments: the ER declared the triplicate a positive response
while the DFR(2x) test did not.
This led us to investigate under what conditions the ST
differs in response determination from the ER and under
what conditions the two statistical DFR tests differ.
Simulation study to compare response determination
with STs and ERs
A simulation study was conducted to assess under what
conditions a ST would differ in response determination
from an ER (Supplementary Figures 1a and 1b). One
thousand hypothetical donors with triplicate wells for
background and experimental conditions were generated.
Spot count data were randomly generated by assuming that
the counts follow a Poisson distribution. The mean spot
count for the background wells was set at 10 per 100,000
PBMCs, reﬂective of the mean in our example data set. The
mean spot count for the experimental wells was varied over
40 values from a mean of 10 to 50 per 100,000 PBMCs.
The signal-to-noise ratio for each experimental condition
was calculated as the mean of the triplicate in the experi-
mental well divided by the mean of the triplicate in the
background well for a given donor. A signal-to-noise ratio
greater than two would be considered a positive response
based on the ﬁrst ER. A one-sided t test was also performed
comparing each experimental condition to its correspond-
ing background. The intra-replicate variation was calcu-
lated as the sample variance of the triplicate/(median of the
triplicate ? 1). The reason for expressing the variability in
this way was to normalize the variation so as to make it
comparable across replicates with large differences in their
spot counts. In the setting where there is a large outlier in
one of the experimental wells compared to the other two
wells, e.g., 50, 2, 6 spots, the median reﬂects the central
tendency of the data but, unlike the mean, is not inﬂuenced
by the outlier (i.e. 50 spots). Hence, we consider the ratio
of the variance to median to identify cases that have large
variability in the experimental well replicates but have a
small median. Since the median response may in some
cases be 0 spots, a 1 is added to the denominator to avoid
division by 0. The response determination based on the
empirical ([2 signal-to-noise ratio) and the statistical rule
(one-sided t test p value B 0.05) is the same for most of the
Table 1 Detection rates per lab based on two empirical rules and three statistical tests (CIP proﬁciency panel phases I–III)
LabID # Expected
responses
Detected based on
empirical rule 1
Detected based on
empirical rule 2
Detected based
on t test
Detected based on
DFR(eq) test
Detected based on
DFR(2x) test
N % N % N % N % N %
Overall 282 165 59 210 74 214 76 212 75 172 61
1 2 1 1 36 21 78 11 6 7 6 1 78 11 36 2
2 2 1 1 25 71 36 21 3 6 2 1 15 2 83 8
3 2 1 1 15 21 78 11 7 8 1 1 78 11 46 7
4 2 1 1 36 21 57 11 4 6 7 1 15 21 04 8
5 21 5 24 5 24 8 38 8 38 4 19
6 1 4 96 4 96 41 2 8 6 1 28 6 96 4
7 2 1 1 46 71 88 61 9 9 0 1 99 01 67 6
8 2 1 1 04 81 46 71 7 8 1 1 67 61 36 2
9 21 16 76 21 100 20 95 20 95 18 86
10 8 6 75 6 75 6 75 6 75 6 75
11 21 11 52 15 71 16 76 16 76 14 67
12 14 7 50 11 79 8 57 9 64 8 57
1 31 5 96 01 49 31 3 8 7 1 38 71 06 7
15 7 4 57 7 100 7 100 7 100 6 86
16 7 5 71 5 71 5 71 6 86 4 57
19 7 7 100 7 100 7 100 7 100 7 100
21 7 4 57 7 100 5 71 6 86 5 71
23 7 5 71 5 71 6 86 6 86 3 43
24 7 4 57 4 57 5 71 5 71 4 57
The ﬁrst line reports the overall results for the whole group. The following rows report the results for the 19 individual centers that participated in
the three phases of the CIP proﬁciency panel program. The ﬁrst column indicates the laboratory IDs, the second column indicates the number of
positive donor-antigen combinations (=responses) that could have been detected under optimal conditions
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However, when the intra-replicate variation is large, the ER
would sometimes consider the triplicate a response while
the ST would not. Conversely, when the intra-replicate
variation was small, the ST would sometimes consider the
triplicate a response while the ER would not. This simu-
lation clearly showed that ERs should only be applied in
settings where the variation within replicates is known and
can be reliably consistent across experiments. It also
demonstrates that STs account for the variation within
reported triplicates. Conversely, the ST may not declare a
large signal-to-noise ratio a positive response if there is
very high variability between replicates. This may indicate
that the declaration of a positive response requires more
compelling evidence for that sample.
Simulation study to compare response determination
with DFR(eq) and DFR(2x) statistical methods
A simulation study was conducted to evaluate the overall
false positive rate and the overall true positive rate (sen-
sitivity) of each DFR method under a variety of conditions.
An overall positive response is declared if at least one
antigen is declared positive. To calculate the overall false
positive rate, background and experimental spot counts for
each donor were generated under the same model. Hence,
for these donors, no response should be detected. Five
thousand donors with triplicate wells for background and
experimental conditions were generated. Spot count data
were randomly generated by assuming that the counts
follow a Poisson distribution. The mean spot count for the
background and experimental (i.e., antigen-containing)
wells was 2, 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 (per
100,000 PBMCs). This was examined in the setting when
testing with two or ten antigen preparations (k = 2, 10). To
assess the overall true positive rate, background spot counts
for each donor were again generated from a Poisson dis-
tribution with background mean spot counts of 2, 5, 10, 15,
20, 25, 30, 35, 40, 45, 50; however, the experimental means
were shifted by 6 (small difference), 20 (moderate differ-
ence), or 50 (large difference) relative to the background
means. All other conditions were the same as in the sim-
ulations for assessing the overall false positive rate.
Figure 1 illustrates the response detection rates versus
the mean background spot counts for both the DFR(eq)
method (closed circle) and the DFR(2x) method (open
Table 2 False positive rates per laboratory based on two empirical rules and three statistical tests (CIP proﬁciency panel phases I–III)
LabID # Expected
non-responses
False positive based
on empirical rule 1
False positive based
on empirical rule 2
False positive
based on t test
Detected based
on DFR(eq) test
Detected based
on DFR(2x) test
N % N % N % N % N %
Overall 196 5 3 33 17 20 10 21 11 4 2
1 15 0 0 4 27 3 20 2 13 0 0
2 1 5 1 7 1 7 170 00 0
3 1 5 0 0 1 7 000 00 0
4 15 0 0 2 13 2 13 1 7 0 0
5 1 5 0 0 0 0 000 00 0
6 12 0 0 3 25 1 8 2 17 1 8
7 1 5 0 0 1 7 001 70 0
8 15 0 0 2 13 2 13 2 13 0 0
9 15 1 7 3 20 2 13 1 7 1 7
1 0 8 0 0 0 0 000 00 0
11 15 1 7 5 33 4 27 5 33 1 7
12 12 0 0 4 33 2 17 3 25 1 8
13 11 0 0 3 27 0 0 1 9 0 0
15 3 0 0 1 33 0 0 0 0 0 0
1 6 3 0 0 0 0 000 00 0
1 9 3 0 0 0 0 000 00 0
21 3 0 0 1 33 1 33 1 33 0 0
23 3 2 67 2 67 2 67 2 67 0 0
2 4 3 0 0 0 0 000 00 0
The ﬁrst line reports the overall results for the whole group. The following rows report the results for the 19 individual centers that participated in
the three phases of the CIP proﬁciency panel program. The ﬁrst column indicates the laboratory IDs, the second column indicates the number of
negative donor-antigen combinations (=negative control donors)
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123circle). The two graphs on the upper row display the
response detection rates in the setting where the mean
number of spots was the same for both the experimental
and background wells (d = 0). In this setting, the response
detection rates for the two methods are expected to be low.
In fact, in 5,000 simulated data sets, the average response
detection rates for at least one of the antigens (k = 2 or 10)
were \5% with the DFR(eq) method and \1% with the
DFR(2x) method across a variety of mean background and
experimental spot counts (2 to 50).
The graphs in the rows 2, 3 and 4 of Fig. 1 display the
overall response detection rates for small (d = 6), moder-
ate (d = 20), or large (d = 50) mean differences. The
response detection rates are high ([80%) in the DFR(eq)
method for the large differences in background and
experimental wells (d = 20 or 50) for a wide range of
background levels (2–50). However, the response detection
rates for the DFR(2x) method are much lower for higher
background levels. This is not surprising given that the null
hypothesis for the DFR(2x) method is less than or equal to
a twofold difference over the background and therefore
background levels that exceed d/2 would generally fail to
reject the null hypothesis and not be considered a positive
response. For small differences in background and exper-
imental wells (d = 6), response detection rates were high
only for low background levels for both DFR(eq) and
DFR(2x) methods although the DFR(eq) method had
higher sensitivity.
These simulations suggest that the DFR(eq) method can
be used in situations where a 5% false positive rate is
acceptable and an experimental mean larger than back-
ground implies a positive response regardless of the level
of that background. The DFR(2x) method is appropriate in
settings where one wants to control the false positive rate at
a lower level, e.g., 1%, or when a fold difference in the
means of experimental versus control well is more of
interest than inequality of means in determining positivity,
e.g., when high background is present.
Intra-replicate variation
Even if a ST declares a positive response, it does not
automatically imply that this result is biologically mean-
ingful. When the spot counts found in the replicates of an
Fig. 1 Simulation study
comparing response
determination using DFR(eq)
and DFR(2x) statistical rules.
The ﬁgure displays the response
detection rate on the y-axis
versus the average background
spot count on the x-axis
(ranging from 2 to 50 spots/
100,000 PBMCs) from 5,000
simulations. In the top row, the
expected mean difference
between the experimental and
control wells is zero; hence,
responses detected are false
positives. The bottom three
rows have an expected
difference of 6, 20 and 50 spots
per 100,000 PBMC over
background. Solid circles
indicate response detection rates
obtained by DFR(eq); open
circles indicate response
detection rate using the
DFR(2x) test. The ﬁrst column
shows the results for k = 2
antigens; the second column
shows the results for k = 10
antigens
1496 Cancer Immunol Immunother (2010) 59:1489–1501
123experimental condition are highly variable, the experi-
mental results are suspect and therefore response detection
results for these replicates would not be believable even
when declared statistically signiﬁcant. However, ‘highly
variable’ is a subjective term that may differ from labo-
ratory to laboratory. We sought to quantify the typical
range of intra-replicate variation found across a broad
variety of different ELISPOT protocols in order to deter-
mine a variability cutoff for recommending that those
replicates should be re-run. Data from the three CIP pro-
ﬁciency panel phases were used to analyze the intra-
replicate variability of experimental results in ELISPOT
assays. Nineteen different laboratories participated in at
least one of the three phases and they reported a total of
717 triplicate experiments (this includes control and
experimental wells). The intra-replicate variation was cal-
culated as the sample variance of the replicates/(median of
the replicates ? 1) as explained in ‘‘Simulation study to
compare response determination with STs and ERs’’.
Figure 2 displays the intra-replicate variation of all 717
experiments reported on the vertical axis with its corre-
sponding rank (percentile) plotted on the horizontal axis.
The minimum intra-replicate variation was zero and the
maximum was 95.4 with the 25th and 75th percentiles (the
middle 50% of reported results) between 0.31 and 2.47
(Fig. 2, inserted table). To determine a ﬁlter for results that
have ‘very high’ variability, we looked at the variance
value at the 95th percentile, 10.13. Based on this ﬁnding,
we would recommend that triplicates with variability
greater than 10 should be considered unreliable data.
Supplementary Table 1a shows the number of replicates
with extremely high variation for each of the 19 partici-
pating laboratories. In depth analysis of the 36 replicates
above the 95th percentile revealed that 7 of the 19 labo-
ratories reported 3 or more triplicates with very large
variation for a total of 28 replicates. The remaining eight
highly variable replicates were reported by six laboratories,
implying that replicates with extremely high variation do
not occur randomly across all participating laboratories but
rather accumulate in a few centers.
Revisiting the data from the three phases (summarized
in Tables 1 and 2), there were only 7 experimental repli-
cates in the 282 positive donor/antigen combinations that
had a large variability ([10). Removing these replicates
with large variability, the response rate was 59% (n = 161/
275) for the ﬁrst ER, 75% (n = 206/275) for the second
ER, 77% (n = 211/275) for the t test, 76% (n = 208/275)
for the DFR(eq) ST, and 61% (n = 169/275) for the
DFR(2x) ST. There were 14 experimental replicates in the
196 donor/antigen combinations not expected to demon-
strate a positive response that had large variability.
Removing the replicates with large variability, the false
positive rate was 2% (n = 3/182) for the ﬁrst ER, 17%
(n = 31/182) for the second ER, 10% (n = 20/182) for the
t test, 10% (n = 19/182) for the DFR(eq) ST, and 2%
(n = 3/182) for the DFR(2x) ST. Hence, the response
detection rates did not change after removing the replicates
with large variability. This is not surprising due to the
small number of replicates with large variability that were
removed from the total data set.
Percentile Classified as
Variance / 
(Median+1)
95th Extremely high  10.13
75th Upper end of average 2.47
50th Average 0.89
25th Lower end of average 0.31
5th Extremely low 0.03
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Fig. 2 Variation of triplicates
expressed as variance/
(median ? 1). Summary of
variation found for 717
replicates that have been
analyzed during three phases of
the CIP ELISPOT proﬁciency
panel program. All results were
ordered in ascending order. The
x-axis shows the percentile rank
and the y-axis indicates the
variance/(median ? 1).
Percentile ranks 5, 25, 50, 75
and 95 are indicated in the
inserted table
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123Estimation of the limit of detection in ELISPOT assays
A second factor to consider when deciding on the relevance
of a positive response is the limit of detection of the
ELISPOT assay. The international conference on harmo-
nization of technical requirements for registration of
pharmaceuticals for human use (ICH) produced a guide-
line on the validation of analytical procedures (http://
www.ich.org/LOB/media/MEDIA417.pdf). In this guide-
line (named Q2R1), the limit of detection is deﬁned as the
lowest amount of analyte in a sample which can be
detected but not necessarily quantiﬁed as an exact value.
The guideline describes three approaches to estimate the
limit of detection for an analytical test: visual evaluation,
signal-to-noise, and response based on standard deviation
and slope. Visual evaluation and response based on stan-
dard deviation and slope are not applicable to the ELISPOT
setting. The signal-to-noise approach compares spot counts
in the experimental wells (signal) to spot counts from the
medium control wells (noise). A signal-to-noise ratio
between 2:1 and 3:1 is generally considered acceptable for
estimating the detection limit. We applied this guideline to
estimate the limit of detection of the ELISPOT assay for a
broad range of protocols.
There were 239 triplicate medium control experiments
reported from all three CIP proﬁciency panel phases. The
mean of these triplicates ranged from 0 to 218 spots per
100,000 PBMCs. The median of the triplicate background
means was 2.1 spots/100,000 PBMCs with the 25th and
75th percentiles, 0.6 spots/100,000 PBMCs and 6.5 spots/
100,000 PBMCs, respectively. This is illustrated in Fig. 3
where the mean medium spot count for all reported repli-
cates is plotted on the vertical axis with its corresponding
rank displayed on the horizontal axis. Using an acceptable
signal-to-noise ratio of 2:1 or 3:1 and choosing as the noise
the median of the average background spot counts (50th
percentile in Fig. 3), we estimate a typical detection limit
for the ELISPOT assay to be 4 spots/100,000 PBMCs or 6
spots/100,000 PBMCs, respectively. For a heterogeneous
group of laboratories that participate in a proﬁciency panel
program, we recommend to use a threshold of 6 spots per
100,000 PBMCs (a signal-to-noise ratio of 3:1) as the
typical limit of detection for an ELISPOT assay. Hence, we
would recommend that even if the results of the ST lead to
the rejection of the null hypothesis, if the mean of the
experimental wells is less than 6 spots/100,000 PBMCs this
ﬁnding should regarded with caution since it is likely that it
is at the limit of detection of the ELISPOT assay, at least
for laboratories with similar average performance as those
included in our proﬁciency panel program.
This limit of detection is close to the threshold selected
for the ﬁrst ER (5 spots/100,000 PBMCs) and would pro-
vide further justiﬁcation for applying a threshold in the ER.
However, it is important to note that the limit of detection
is based on the average background from all the laborato-
ries. This means that laboratories with lower background
spot counts than the average of the panel will likely have a
limit of detection that is lower than 6 spots/100,000
PBMCs. Similarly, laboratories with larger background
spot counts than the average of the panel will likely have a
limit of detection that is higher than 6 spots/100,000
PBMCs. Therefore, the threshold or limit of detection
might be too strict for some laboratories in declaring a
response positive and not strict enough for others. This is
clearly illustrated in supplementary Table 1B that shows
the mean number of spots 100,000 PBMCs in the medium
control as reported by each of the 19 participating labora-
tories. The mean background spot production observed in
Percentile Classified as Spots
95th Extremely high  55.40
75th Upper end of average 6.33
50th Average 2.17
25th Lower end of average 0.6
5th Extremely low 0.07
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Fig. 3 Background spots
production per 100,000 PBMCs.
Estimation of the limit of
detection based on 239 reported
replicates from three phases of
the CIP ELISPOT proﬁciency
panel program. All results were
ordered in ascending order. The
x-axis shows the percentile rank
and the y-axis indicates the
reported mean spot number.
Percentile ranks 5, 25, 50, 75
and 95 are indicated in the
inserted table. Values between
the 25th and 75th percentile
were considered as being
average for a typical ELISPOT
protocol
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123individual laboratories across all tested donors differed
signiﬁcantly between the participating laboratories and
could be very low (0.2 spots per 100,000 PBMCs) to very
high (58.1 spots per 100,000 PBMCs).
Discussion
The goal of this paper was to describe and compare
objective methods that distinguish between positive and
negative responses in the ELISPOT assay and to facilitate
their widespread application. Two approaches, empirical
and statistical, were described and applied to large data sets
obtained from several proﬁciency panels including many
laboratories operating with their own ELISPOT reagents
and protocols. Simulation studies were also conducted to
compare the empirical and statistical approaches. The ﬁrst
ER yielded lower response detection rates but had very low
false positive rates in contrast to the STs and the second ER
which had higher response rates but also had a larger
number of false positives. The main advantage of an ER
such as the one proposed by Dubey et al. is that it is
generally intuitive and easy to apply. The main drawback is
that it is not clear how the false positive rate is being
controlled when multiple antigens are considered, as is
common practice. To appropriately justify the thresholds
selected for the ER, a laboratory would need to determine
the false positive rates of various thresholds for a given
protocol. This would require testing a large number of
samples of negative controls and positive donors, which
would be costly and time consuming. Additionally, the
variability of the replicates is not taken into account in the
determination of the rule when the average of the replicates
is used. Therefore, as demonstrated in the ﬁrst simulation
study (Supplementary Figures 1a and 1b), if one of the
replicate values is much larger than the others in that
replicate, the resulting average would be large and might
cause an incorrect classiﬁcation of response (false posi-
tive). Also the reverse can occur where there is low vari-
ability in replicates but the average is just below the
speciﬁed positivity threshold value. In this setting, a
response may be missed (false negative). Furthermore,
there is no formal way to adjust for multiple antigen
comparisons and so the underlying false positive rate is
unknown even if the thresholds for the rule were set based
on a speciﬁc false positive rate.
The main advantage of a ST is that it can be applied
without prior knowledge of the performance criteria of the
test, provided the assumptions of the ST are valid. In
addition, STs allow control of the false positive rate by the
setting of the threshold for acceptance (alpha). As the t test
is not necessarily appropriate due to the required assump-
tion of a parametric distribution of the test statistic, we
favor the use of non-parametric tests. Both DFR methods
(DFR(eq) and DFR(2x)) control the overall false positive
rate when testing multiple antigens and avoid parametric
assumptions about the data. These methods can now be
readily implemented in freely available software or via a
web interface (http://www.scharp.org/zoe/runDFR/).
Response determination is made based on a compar-
ison of the medium control and experimental wells. The
background values for spot production in ELISPOT can
differ between several donors and between different time
points for one and the same donor within the observation
period. Any increase in the background spot production
will directly impact on the sensitivity of the method as
the acceptance of a result as a positive response is
directly linked to the background. To increase the power
of the test, it would be ideal to have more replicate wells
for both control and experimental conditions. Even an
increased number of replicates for the control wells
alone would already increase the power to detect a
response [20, 21]. This is particularly true in the setting
where many antigens are tested since the control wells
are used multiple times for comparison (once with each
antigen). Intuitively, this makes sense because with more
control wells one can be more certain about the under-
lying background which is being used as the basis for
comparison to the antigen responses. In the setting where
duplicate or triplicate experimental wells will be per-
formed, Hudgens et al. demonstrate that having six
background wells increased the sensitivity of the test
from 0.61 to 0.75 for a (2,2) versus a (6,2) format. To
increase the power to detect differences between spot
counts in experimental versus medium control wells, we
therefore recommend using six medium control wells for
each sample, whenever possible. Alternatively, utilizing
four wells for both, medium control and experimental
conditions, would give similar power to detect differ-
ences [21].
In addition to applying a ST, we further recommend that
replicates with variability greater than 10, deﬁned as the
sample variance of the replicates/(median of the repli-
cates ? 1), should be excluded and/or re-run prior to
response determination as replicates with such high varia-
tion are likely to be artefacts and should not be considered
reliable to use for response determination (Fig. 2). In the
setting where the responses are expected to be large, a less
strict variability cutoff can be used. For example, the HIV
Vaccine Trials Network uses a variability cutoff of 25 [21]
based on their laboratory experience.
Our data also suggest that experimental replicates
demonstrated to be a response by one of the response
detection rules but having a mean below 6 spots per
100,000 PBMCs should be viewed with caution (Fig. 3).
Depending on the speciﬁc study design, some investigators
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123might have valid reasons for introducing a threshold spot
count below which results are not considered of interest.
Both the ﬁlters for large variability and estimated limit
of detection are based on data generated by a variety of
representative ELISPOT protocols. An individual labora-
tory may have different thresholds that are applicable only
to them. Laboratories that have very low intra-replicate
variability may set a lower threshold for ﬁltering out rep-
licates that are experimentally problematic. Laboratories
that consistently observe absent or minimal background
spot production may assume a lower limit of detection than
the one proposed in this paper. Similarly, individual labo-
ratories that regularly observe background spot production
above 2 spots per 100,000 PBMC, which is very common
(Supplemental Table 1), should consider limits of detection
that are above our estimated value. In all instances, it is
important that investigators critically review their own test
performance to determine their laboratory-speciﬁc esti-
mates for high variability and limit of detection. Any
threshold proposed should be justiﬁed based on experi-
mental results.
Another strategy to increase the validity of generated
data sets could be the regular use of positive control rep-
licate which may either (a) consist of a non-speciﬁc posi-
tive control stimulus that is added to a donor’s PBMCs or
(b) PBMC from a control donor known to be reactive
against a given antigen. Provided the positive control
replicate does not pass the positivity call of the applied
response determination rule or statistical test, the results
from the corresponding ELISPOT plate should be regarded
with caution as they could contain false negative results.
In summary, both ERs and STs may serve as appropriate
response deﬁnition criteria; however, ERs need to be jus-
tiﬁed using data sets from control populations and are only
valid for the test protocol used to deﬁne the thresholds for
acceptance. In contrast, STs maintain validity independent
of the test protocol applied provided the assumptions of the
statistical test are met. As such we would recommend that a
non-parametric ST should be used to determine if a
response is detected. To increase the sensitivity in detect-
ing a response using a ST, six replicates (instead of only
three) should be performed for the medium control wells or
four wells each for both medium control and experimental
conditions. Further, to factor in biological plausibility and
relevance, we recommend ﬁltering out replicates with high
variation and viewing with caution experimental replicates
below the estimated limit of detection. The DFR(eq)
method would be preferred in the setting where a 5% false
positive rate is acceptable and it is of interest to detect even
low to moderate positive responses regardless of the level
of that background. The DFR(2x) method is appropriate in
settings where one wants to control the false positive rate at
a lower level, e.g., 1%, or when a fold difference in the
means of experimental versus control wells is more of
interest than inequality of means in determining positivity.
To enable broad use of the recommended non-para-
metric STs described in this paper, a web-based interface
was created: http://www.scharp.org/zoe/runDFR/. Instruc-
tions are provided in the electronic supplemental material.
The original R code is available for download and a sample
scenario for illustrative purposes is provided on the web-
site. This tool provides two methods for objective response
determination that can be easily implemented in any lab,
potentially leading to greater comparability of results
across institutions. In addition to the web-based tool, we
developed an Excel macro for user-friendly implementa-
tion of the DFR method for investigators preferring the use
of Excel. This macro will be made freely available upon
request.
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